Ronald Bailey Says Leave 23andMe Alone

In November the Food and Drug
Administration (FDA) warned the direct-to-consumer gene testing
company 23andMe to stop marketing its $99 genotype screening test.
The FDA’s letter gave 23andMe 15 days to respond, warning that if
the agency didn’t like what it heard, the potential results could
“include, but are not limited to, seizure, injunction, and civil
money penalties.” Ronald Bailey says that despite the FDA’s parade
of horrible hypotheticals, the bigger risk is that increased
regulation will slow down the progress of beneficial genetic
testing and treatment.

View this article.